Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction

ConditionsAcute Myocardial Infarction With ST Elevation Intelligent Management Platform Early Warning

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorHui Chen

About this trial

The goal of this observational study is to learn about the effectiveness of an artificial intelligence-based early warning system for predicting adverse events in patients with acute myocardial infarction (AMI). The main question it aims to answer is:

Does an AI-based early warning system improve the assessment and prediction of adverse events across the full course of AMI care (from prevention to diagnosis, treatment, and rehabilitation)?

Participants who are receiving routine medical care for AMI in tertiary hospitals will have their multimodal medical data (clinical records, diagnostic tests, imaging, treatment pathways) collected and analyzed. Data will be integrated using innovative cross-modal representation methods and predictive models. The study will follow patients during their hospital stay and subsequent clinical follow-up to evaluate the feasibility, accuracy, and clinical value of the AI-based early warning system.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Hospitalized patients who meet the diagnostic criteria for acute myocardial infarction. 2. Patients who agree to participate and sign the informed consent form.

Disqualifiers

1. Patients with terminal malignant tumors and an expected survival time of less than 3 months. 2. Patients with complete disability and inability to communicate. 3. Patients unable to comply with follow-up.

Trial population

1. Retrospective Study Population: Data were obtained from the Cardiovascular Center Database (CBDBank) of Beijing Friendship Hospital. CBDBank is a continuously collected sample dataset of patients with acute coronary syndrome since January 2013. A total of 1,000 patients with acute myocardial infarction admitted to Beijing Friendship Hospital, Capital Medical University, from January 2017 to December 2019 were included in the retrospective cohort. After discharge, all patients received scheduled telephone follow-ups at 1 month, 3 months, 6 months, and annually thereafter, with continuous follow-up for 3 years. 2. Prospective Study Population: A total of 800 patients with acute myocardial infarction admitted to the Cardiovascular Center of Beijing Friendship Hospital from July 2023 to July 2026 will be enrolled in the prospective cohort. Randomization will be performed using random codes, and prognosis prediction will be conducted using either the predictive system or traditional met

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

1,400 Participants

are grouped into 2 trial groups

Group A: BFH

Group B: AZH

Trial outcomes

Primary outcomes

MACCE

Cardiac death All-cause mortality Malignant arrhythmia Non-fatal recurrent myocardial infarction Non-fatal stroke Unplanned repeat revascularization Rehospitalization for heart failure

Time frame

1-3 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Hui Chen

Lead sponsor

Beijing Friendship Hospital

Sponsor institution

Source ClinicalTrials.gov

Apply now